Impact of abuse‐deterrent OxyContin on prescription opioid utilization

@article{Hwang2015ImpactOA,
  title={Impact of abuse‐deterrent OxyContin on prescription opioid utilization},
  author={Catherine S. Hwang and Hsien-Yen Chang and G Caleb Alexander},
  journal={Pharmacoepidemiology and Drug Safety},
  year={2015},
  volume={24},
  pages={197 - 204}
}
We quantified the degree to which the August 2010 reformulation of abuse‐deterrent OxyContin affected its use, as well as the use of alternative extended‐release and immediate‐release opioids. 
Measuring prescription opioid misuse and its consequences
TLDR
The need new analytical strategies and techniques to understand the medications involved, user characteristics and other factors needed to address the prescription drug misuse epidemic in the USA increased during the 1990s to 2010. Expand
Abuse-Deterrent Opioids
  • Medicine
  • JAMA
  • 2018
TLDR
An oxycodone tablet formulation (Roxybond – Inspirion) is approved that is the first immediaterelease opioid product FDA-approved to include claims of abuse deterrence in its labeling. Expand
California Health Benefits Review Program Analysis of California Assembly Bill AB 623 Abuse-Deterrent Opioid Analgesics
Author(s): Fix, Margaret; Abbott, Bruce; Melnikow, Joy; Ritley, Dominique; Soulsby, Meghan; Lavarreda, Shana; Pantely, Susan; Holtsman, Mark; Lewis, John; Fulton, Brent
Anticipated and unanticipated consequences of abuse deterrent formulations of opioid analgesics
TLDR
This is an important, despitesome study, which raises important public health concerns, and some history for people well-versed in the current epidemic of prescriptionopioid abuse might be helpful. Expand
Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
TLDR
Despite methods to circumvent the abuse deterrent mechanism, abuse and diversion of OxyContin decreased promptly following the introduction of a crush- and solubility- resistant formulation and continued to decrease over the subsequent 5 years. Expand
Abuse-Deterrent Opioid Formulations.
TLDR
Postmarketing epidemiological studies are required for all opioid formulations that have claims of abuse deterrence in their labeling to assess whether a formulation has been associated with meaningful reductions in adverse clinical outcomes related to abuse and misuse. Expand
Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.
TLDR
Opioid dispensing and prescription opioid overdoses decreased substantially after 2 major changes in the pharmaceutical market in late 2010, and pharmaceutical market interventions may have value in combatting the prescription opioid overdose epidemic. Expand
Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program.
TLDR
The results of this study indicate that both prescription spending and physician and pharmacy spending combined may be increased with the use of these new products because of higher pricing. Expand
Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice.
TLDR
Their relatively high costs, uncertain insurance policies, and limited data on pharmacoeconomics warrant collaborative monitoring and assessment by government agencies, pharmaceutical manufacturers, and data analysis services to define their therapeutic role in the future. Expand
Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System.
TLDR
Data to date from Poison Center, Drug Diversion, and Treatment Centers combined suggest a low, but present public health burden related to tapentadol, and a broad and carefully designed postmarketing mosaic is presented. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 45 REFERENCES
Effect of abuse-deterrent formulation of OxyContin.
TLDR
After the new formulation of the widely abused prescription opioid OxyContin was introduced, patients reported that they used OxyContin less often and other drugs (including heroin) more often. Expand
Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics
TLDR
The effects of physicochemical barriers to crushing and dissolving on safety outcomes associated with extended‐release oxycodone tablets (OxyContin) using a national surveillance system of poison centers are evaluated. Expand
Abuse-deterrent opioid formulations: Are they a pipe dream?
TLDR
Abuse-deterrent formulations have the potential to reduce the public health burden of prescription opioid abuse, but they will require not only technically successful formulations, but also appropriate scientific assessment, widespread market penetration, and rational expectations of their benefits. Expand
Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.
TLDR
It is indicated that the abuse, therapeutic errors, and diversion of ERO declined following the introduction of a tamper-resistant reformulation of the product. Expand
A national epidemic of unintentional prescription opioid overdose deaths: how physicians can help control it.
TLDR
Patients using these drugs often have a combination of painful conditions, substance abuse, and other forms of mental illness, and Psychiatrists need to be informed regarding this problem to partner effectively with both pain specialists and primary care providers in their community. Expand
Tampering with Prescription Opioids: Nature and Extent of the Problem, Health Consequences, and Solutions
TLDR
The seriousness of health outcomes associated with tampering with POs warrants the development of PO formulations that prevent or deter tampering, and methods of abuse vary widely by product. Expand
Abuse-resistant painkillers get mixed FDA response
TLDR
The FDA has rejected Remoxy, a new abuse-deterrent formulation of oxycodone developed by Pfizer and Acura Pharmaceuticals that combines a crush-resistant technology similar to that found in Oxecta with a time-release element. Expand
Medicaid Prior Authorization and Controlled-Release Oxycodone
TLDR
PA impact varied by state and was less dramatic than previously described Medicaid PA effects, suggesting CR oxycodone is relatively refractory to PA, suggesting effective prescription management strategies are needed. Expand
Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.
TLDR
Preliminary findings are presented indicating that 8 outcome measures of abuse of a reformulated ER oxycodone were lower than that for original ER oxyCodone historically, particularly through nonoral ROAs that require tampering, in a sentinel sample of individuals assessed for substance use problems for treatment planning. Expand
Prescription opioid abuse: challenges and opportunities for payers.
TLDR
Reimbursement policies, incentives, and health technology systems that encourage physicians to use universal precautions, to consult prescription monitoring program (PMP) data, and to implement Screening, Brief Intervention, and Referral to Treatment protocols have a high potential to reduce insurer risks while addressing a serious public health problem. Expand
...
1
2
3
4
5
...